Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal mel

Trial Details

NCT ID
NCT04282044
Phase
PHASE1
Sponsor
BioEclipse Therapeutics
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • CRX100 suspension for infusion
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • La Jolla, California, United States|32.84727,-117.2742
  • Stanford, California, United States|37.42411,-122.16608

Key Eligibility Criteria

  • Subjects must meet all the following criteria to be enrolled in this study:
  • Age ≥18 years at the time of consent.
  • Written informed consent in accordance with national, local, and institutional guidelines obtained prior to any study procedures. (Screening assess…
  • Subjects must have histologically confirmed diagnosis of one of the following tumors: triple negative adenocarcinoma of the breast (human epidermal…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →